The role of endothelial cell dysfunction in the cardiovascular mortality of RA

International Reviews of Immunology

Volumn 21, Issue 1, 2002, Pages 1-17

  Bacon, P A ^a   Raza, K ^a   Banks, M J ^a   Townend, J ^a   Kitas, G D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atheroma; Endothelial dysfunction; Immune inflammation; Rheumatoid arthritis; Vasculitis

Indexed keywords

ARTERIOSCLEROSIS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMAN; VASCULITIS; HUMANS;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; HUMAN; MORTALITY; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; VASCULAR ENDOTHELIUM; VASCULITIS;

EID: 0035986996     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180210413     Document Type: Article

References (66)

1. Long term outcomes in rheumatoid arthritis
2. Mortality in rheumatoid arthritis: Have we made an impact in 4 decades?
3. Inflammation-mediated rheumatic diseases and atherosclerosis
4. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis
5. Mortality amongst arthrities
6. Factors influencing mortality in rheumatoid arthritis
7. The mortality of rheumatoid arthritis
8. Ten year mortality and cause of death in patients with rheumatoid arthritis
9. Visceral lesions associated with chronic infectious (rheumatoid) arthritis
10. Cardiac involvement in rheumatoid disease
11. Prevalence of coronary heart disease in Icelandic men 1968-1986. The Reykjavik study
12. Heart disease in rheumatoid arthritis
13. Increased mortality among patients with rheumatoid arthritis, but where RA does not appear on the death certificate
14. Patients' disability in RA may influence doctors' perception of suitability for risk assessment of CHD
15. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease
16. Cardiovascular mortality in rheumatoid arthritis: How harmful are corticosteroids
17. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity
18. Increased mortality in seropositive patients during the early years of inflammatory polyarthritis
19. Progression of atherosclerosis in common cartoid artery (CCA) of patients with Rheumatoid Arthritis (RA) - Measurement of intimamedia thickness (IMT) by ultrasonography
20. Dyslipidamia in rheumatoid arthritis
21. The significance of vascular inflammation in rheumatoid arthritis
22. Inflammation, aspirin and the risk of cardiovascular disease in apparently health men
23. Atherosterosis - An inflammatory disease
24. Retransplantation for severe accelerated coronary disease in heart transplantation recipients
25. Cardiac transplant vasculopathy
26. Systemic rheumatoid vasculitis: A clinical and laboratory study of 50 cases
27. Suppression of inflammation in primary systemic vasculitis restores endothelial function: Lessons for atherosclerosis disease?
28. Development and initial validation of the vasculitis damage index (VDI) for the standardised clinical assessment of damage in the systemic vasculitides
29. Damage occurs early in systemic vasculitis and is an index of outcome
30. Small-vessel vasculitis
31. Endothelial dysfunction and primary systemic vasculitis (PSV): Reversibility and impairment by disease group
32. Primary systemic vasculitis and endothelial: Analysis by disease subgroup and vascular bed
33. Abnormalities of endothelial function in patients with predialysis renal failure
34. Classical versus non-renal wegeners granulomatosis
35. Pathogenesis of ANCA-associated systemic vasculitis
36. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
37. What you should know about PR3-ANCA. An introduction
38. Inflammatory cytokines impair endothelium-dependent dilation in human veins in vivo
39. Acute systemic inflammation impairs endothelium-dependent dilatation in humans
40. Role of cytokines in rheumatoid arthritis
41. Infection, inflammation and infarction: Does acute endothelial dysfunction provide a link
42. Atherosclerosis
43. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
44. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities
45. Long-term effects of pravastatin on plasma concentration of C-reactive protein
46. The pathogenesis of atherosclerosis I
47. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
48. Oxidative stress and cardiovascular disease
49. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study
50. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus
51. A study of endothelial function in systemic lupus erythematosus (SLE)
52. Endothelial stunning following a brief exposure to endotoxin; a mechanism to link infection to infarction?
53. Administration of tumor necrosis factor-alpha in vivo depresses endothelium dependent relaxation
54. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells
55. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs
56. De of immunopathological abnormalities in normal skin
57. The incidence of rheumatoid vasculitis in the Norwich Health Authority
58. Normal skin in rheumatoid arthritis
59. Arteritis of striated muscle in rheumatoid arthritis
60. Labial salivary gland biopsy assessment in rheumatoid vasculitis
61. 2 to this atherogenic profile
62. Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis
63. Perturbation of the T cell repertoire in patients with unstable angina
64. CD4+ CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems